Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome
BackgroundThis study aims to investigate the prognostic significance of transthyretin in newly diagnosed myelodysplastic syndromes (MDS).MethodsThe clinical, laboratory, and follow-up data of 280 newly diagnosed patients with MDS were collected. The relationship between serum transthyretin levels an...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2023.1125768/full |
| _version_ | 1811158958831828992 |
|---|---|
| author | Ying Chen Ying Chen Tingting Niu Tingting Niu Ting Chen Ting Chen Yue Wu Yue Wu Duobing Zou Duobing Zou Cong Shi Cong Shi Ying Wu Ying Wu Zhaoyi Zhang Zhaoyi Zhang Ningning Wu Ningning Wu Yi Zhang Yi Zhang Xiao Yan Xiao Yan Lixia Sheng Lixia Sheng Dingfeng Lv Guifang Ouyang Guifang Ouyang Xueqin Chen Qitian Mu Qitian Mu |
| author_facet | Ying Chen Ying Chen Tingting Niu Tingting Niu Ting Chen Ting Chen Yue Wu Yue Wu Duobing Zou Duobing Zou Cong Shi Cong Shi Ying Wu Ying Wu Zhaoyi Zhang Zhaoyi Zhang Ningning Wu Ningning Wu Yi Zhang Yi Zhang Xiao Yan Xiao Yan Lixia Sheng Lixia Sheng Dingfeng Lv Guifang Ouyang Guifang Ouyang Xueqin Chen Qitian Mu Qitian Mu |
| author_sort | Ying Chen |
| collection | DOAJ |
| description | BackgroundThis study aims to investigate the prognostic significance of transthyretin in newly diagnosed myelodysplastic syndromes (MDS).MethodsThe clinical, laboratory, and follow-up data of 280 newly diagnosed patients with MDS were collected. The relationship between serum transthyretin levels and overall survival (OS) and leukemia-free survival (LFS) were analyzed by Kaplan–Meier analysis and Cox Regression Model.ResultIn the MDS cohort, there were 121 cases in the low transthyretin group and 159 cases in the normal transthyretin group. MDS patients with decreased transthyretin had a higher risk score on the Revised International Prognostic Scoring System (IPSS-R) (p = 0.004) and on the molecular IPSS (IPSS-M) (p = 0.005), a higher frequency of TP53 mutation (p < 0.0001), a shorter OS (p < 0.0001) and LFS (p < 0.0001). Multivariate analyses showed that higher IPSS-R and IPSS-M score were adverse factors for OS (p = 0.008 and p = 0.015, respectively) and LFS (p = 0.024 and p = 0.005, respectively). Mutations of TP53 and NRAS were also poor factors for LFS (p = 0.034 and p = 0.018, respectively). Notably, decreased transthyretin was an independent adverse predictor for OS (p = 0.009, HR = 0.097, 95%CI, 0.017–0.561) but not for LFS (p = 0.167) when IPSS-R was included in the Cox regression model and an independent poor one for OS (p = 0.033, HR = 0.267, 95%CI, 0.080–0.898) and LFS (p = 0.024, HR = 0.290, 95%CI, 0.099–0.848) while IPSS-M involved.ConclusionThe results indicate that decreased transthyretin could be an independent adverse prognostic factor in patients with MDS and may provide a supplement to IPSS-R and IPSS-M. |
| first_indexed | 2024-04-10T05:33:09Z |
| format | Article |
| id | doaj.art-28f37d3a28a84596a26cf0d92a6467f5 |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-04-10T05:33:09Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-28f37d3a28a84596a26cf0d92a6467f52023-03-07T05:22:59ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2023-03-011010.3389/fnut.2023.11257681125768Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndromeYing Chen0Ying Chen1Tingting Niu2Tingting Niu3Ting Chen4Ting Chen5Yue Wu6Yue Wu7Duobing Zou8Duobing Zou9Cong Shi10Cong Shi11Ying Wu12Ying Wu13Zhaoyi Zhang14Zhaoyi Zhang15Ningning Wu16Ningning Wu17Yi Zhang18Yi Zhang19Xiao Yan20Xiao Yan21Lixia Sheng22Lixia Sheng23Dingfeng Lv24Guifang Ouyang25Guifang Ouyang26Xueqin Chen27Qitian Mu28Qitian Mu29Laboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaHematology Department, Ningbo First Hospital, Ningbo, Zhejiang, ChinaMedical School of Ningbo University, Ningbo, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaMedical School of Ningbo University, Ningbo, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaHematology Department, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaHematology Department, Ningbo First Hospital, Ningbo, Zhejiang, ChinaDepartment of Blood Transfusion, Ningbo First Hospital, Ningbo, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaHematology Department, Ningbo First Hospital, Ningbo, Zhejiang, ChinaDepartment of Traditional Medicine, Ningbo First Hospital, Ningbo, Zhejiang, ChinaLaboratory of Stem Cell Transplantation, Ningbo First Hospital, Ningbo, Zhejiang, ChinaNingbo Clinical Research Center For Hematologic Malignancies, Ningbo, Zhejiang, ChinaBackgroundThis study aims to investigate the prognostic significance of transthyretin in newly diagnosed myelodysplastic syndromes (MDS).MethodsThe clinical, laboratory, and follow-up data of 280 newly diagnosed patients with MDS were collected. The relationship between serum transthyretin levels and overall survival (OS) and leukemia-free survival (LFS) were analyzed by Kaplan–Meier analysis and Cox Regression Model.ResultIn the MDS cohort, there were 121 cases in the low transthyretin group and 159 cases in the normal transthyretin group. MDS patients with decreased transthyretin had a higher risk score on the Revised International Prognostic Scoring System (IPSS-R) (p = 0.004) and on the molecular IPSS (IPSS-M) (p = 0.005), a higher frequency of TP53 mutation (p < 0.0001), a shorter OS (p < 0.0001) and LFS (p < 0.0001). Multivariate analyses showed that higher IPSS-R and IPSS-M score were adverse factors for OS (p = 0.008 and p = 0.015, respectively) and LFS (p = 0.024 and p = 0.005, respectively). Mutations of TP53 and NRAS were also poor factors for LFS (p = 0.034 and p = 0.018, respectively). Notably, decreased transthyretin was an independent adverse predictor for OS (p = 0.009, HR = 0.097, 95%CI, 0.017–0.561) but not for LFS (p = 0.167) when IPSS-R was included in the Cox regression model and an independent poor one for OS (p = 0.033, HR = 0.267, 95%CI, 0.080–0.898) and LFS (p = 0.024, HR = 0.290, 95%CI, 0.099–0.848) while IPSS-M involved.ConclusionThe results indicate that decreased transthyretin could be an independent adverse prognostic factor in patients with MDS and may provide a supplement to IPSS-R and IPSS-M.https://www.frontiersin.org/articles/10.3389/fnut.2023.1125768/fullmyelodysplastic syndromestransthyretinprognosisIPSS-RIPSS-M |
| spellingShingle | Ying Chen Ying Chen Tingting Niu Tingting Niu Ting Chen Ting Chen Yue Wu Yue Wu Duobing Zou Duobing Zou Cong Shi Cong Shi Ying Wu Ying Wu Zhaoyi Zhang Zhaoyi Zhang Ningning Wu Ningning Wu Yi Zhang Yi Zhang Xiao Yan Xiao Yan Lixia Sheng Lixia Sheng Dingfeng Lv Guifang Ouyang Guifang Ouyang Xueqin Chen Qitian Mu Qitian Mu Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome Frontiers in Nutrition myelodysplastic syndromes transthyretin prognosis IPSS-R IPSS-M |
| title | Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome |
| title_full | Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome |
| title_fullStr | Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome |
| title_full_unstemmed | Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome |
| title_short | Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome |
| title_sort | decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome |
| topic | myelodysplastic syndromes transthyretin prognosis IPSS-R IPSS-M |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2023.1125768/full |
| work_keys_str_mv | AT yingchen decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yingchen decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT tingtingniu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT tingtingniu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT tingchen decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT tingchen decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yuewu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yuewu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT duobingzou decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT duobingzou decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT congshi decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT congshi decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yingwu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yingwu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT zhaoyizhang decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT zhaoyizhang decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT ningningwu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT ningningwu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yizhang decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT yizhang decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT xiaoyan decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT xiaoyan decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT lixiasheng decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT lixiasheng decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT dingfenglv decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT guifangouyang decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT guifangouyang decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT xueqinchen decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT qitianmu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome AT qitianmu decreasedtransthyretinpredictsapoorprognosisinprimarymyelodysplasticsyndrome |